SLN

Silence Therapeutics Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↓ 0/10
  • Momentum↓ 3/10
Silence Therapeutics sales and earnings growth
SLN Growth
Low
  • Revenue Y/Y↑ 27.31%
  • EPS Y/Y↓ 0.00%
  • FCF Y/Y↓ -31.35%
Silence Therapeutics gross and profit margin trends
SLN Profitability
Fair
  • Gross margin ↑ 90.50%
  • EPS margin↓ -255.10%
  • ROIC↓ -97.50%
Silence Therapeutics net debt vs free cash flow
SLN Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -6.3

Silence Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗